Clinical trial
A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
NCT02669017 is registered in ClinicalTrials.gov with ADC Therapeutics S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
- Lead sponsor
- ADC Therapeutics S.A.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 31, 2016
- Completion date
- February 21, 2019
- Enrollment
- 183 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.
burkitt's lymphoma, chronic lymphocytic leukemia, lymphoma, follicular, lymphoma, large b-cell, diffuse, lymphoma, mantle-cell, lymphoma, marginal zone, non-hodgkin lymphoma, primary mediastinal b-cell lymphoma, waldenstrom macroglobulinemia